Tyrosine kinase inhibitors - Small molecular weight compounds Inhibiting EGFR

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 3, 2009, Pages 308-321

  Hegymegi Barakonyi, Bálint ^a,b   Eros, Dániel ^a   Szántai Kis, Csaba ^a,b   Breza, Nóra ^a,b   Bánhegyi, Péter ^a,b   Szabó, Gábor Viktor ^b   Várkondi, Edit ^b   Peták, István ^b,c   Orfi, László ^a,b   Kéri, György ^a,b  

^a Vichem Chemie Ltd   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c KPS Medical Biotechnology and Healthcare Services Ltd   (Hungary)

Author keywords

EGFR; EGFR kinase inhibitor; Multiple targets; Signal transduction

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BEVACIZUMAB; BIBW 2992; BMS 690514; CANERTINIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; HKI 357; LAPATINIB; PACLITAXEL; PAZOPANIB; PELITINIB; PEMETREXED; RAPAMYCIN; SULINDAC; SUNITINIB; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; XL 647;

ACUTE GRANULOCYTIC LEUKEMIA; BLADDER CANCER; BRAIN CANCER; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CELL STRAIN MCF 7; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG BINDING; DRUG EFFICACY; DRUG ERUPTION; DRUG INHIBITION; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; ENDOMETRIUM CANCER; EYE DISEASE; GENE AMPLIFICATION; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MOUTH CANCER; NAUSEA AND VOMITING; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THYROID CANCER; TREATMENT RESPONSE; URINARY TRACT CANCER; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR WEIGHT; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL MOLECULE LIBRARIES;

EID: 67650215281     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Gschwind A, Fischer OM, Ullrich A: Timeline - The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer (2004) 4(5):361-370.
2. Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G: Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol (2007) 39(7-8):1416-1431.
3. Ghoreschi K, Laurence A, O'Shea JJ: Selectivity and therapeutic inhibition of kinases: To be or not to be? Nat Immunol (2009) 10(4):356-360.
4. Karaman M, Herrgard S, Treiber D, Gallant P, Atteridge C, Campbell B, Chan K, Ciceri P, Davis M, Edeen P, Faraoni R et al: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 26(1):127-132.
5. Bencardino K, Manzoni M, Delfanti S, Riccardi A, Danova M, Corazza GR: Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: Results and open issues. Intern Emerg Med (2007) 2(1):3-12.
6. Basti S: Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs (2007) 30(4):S10-S16.
7. Sequist L, Bell D, Lynch T, Haber D: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol (2007) 25(5):587-595.
8. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R et al: Multi-institutional randomized phase II trial of geftinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol (2003) 21(12):2237-2246.
9. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS et al: Effcacy of geftinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial. J Am Med Assoc (2003) 290(16):2149-2158.
10. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U et al: Geftinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol (2004) 22(5):777-784.
11. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK et al: Geftinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol (2004) 22(5):785-794.
12. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K: Geftinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet (2005) 366(9496):1527-1537.
13. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol (2004) 22(16):3238-3247.
14. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 23(25):5892-5899.
15. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva lung cancer investigation trial. J Clin Oncol (2007) 25(12):1545-1552.
16. Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A et al: Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2006) 24(24):3831-3837.
17. Pham D, Kris MG, Riely GJ, Sarkaria IS, McDonough T, Chuai S, Venkatraman ES, Miller VA, Ladanyi M, Pao W, Wilson RK et al: Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol (2006) 24(11):1700-1704.
18. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 353(2):123-132.
19. Pao W, Miller V, Politi K, Riely G, Somwar R, Zakowski M, Kris M, Varmus H: Acquired resistance of lung adenocarcinomas to geftinib or erlotinib is associated with a second mutation in the EGFR kinase domain.PLOS Med (2005) 2(3):225-235.
20. Sordella R, Bell DW, Haber DA, Settleman J: Geftinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 305(5687):1163-1167.
21. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to geftinib. N Engl J Med (2005) 352(8):786-792.
22. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell (2007) 11(3):217-227.
23. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 25(22):3230-3237.
24. Wood ER, Shewchuk LM, Ellis B, Brignola P, Brashear RL, Caferro TR, Dickerson SH, Dickson HD, Donaldson KH, Gaul M, Griffn RJ et al: 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno [2,3-d]pyrimidin-4-anilines as tunable covalent modifers of ErbB kinases. Proc Natl Acad Sci USA (2008) 105(8): 2773-2778.
25. Varkondi E, Pinter F, Kiss R, Schwab R, Breza N, Orf L, Keri G, Petak I: Biochemical assay-based selectivity profling of clinically relevant kinase inhibitors on mutant forms of EGF receptor. J Recept Signal Transduct (2008) 28(3):295-306.
26. Bridges AJ, Zhou H, Cody DR, Rewcastle GW, McMichael A, Showalter HD, Fry DW, Kraker AJ, Denny WA: Tyrosine kinase inhibitors .8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7- dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem (1996) 39(1):267-276.
27. Partik G, Hochegger K, Schorkhuber M, Marian B: Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro. J Cancer Res Clin Oncol (1999) 125(7):379-388.
28. Pinter F, Papay J, Almasi A, Sapi Z, Szabo E, Kanya M, Tamasi A, Jori B, Varkondi E, Moldvay J, Szondy K et al: Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn (2008) 10(2):160-168.
29. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR et al: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res (2006) 66(3):1630-1639.
30. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med (2006) 355(26):2733-2743.
31. Cristofanilli M, Boussen H, Baselga J, Lluch A, Ben Ayed F, Friaha M, Ben Ahmed S, Hurley J, Johnston S, Kaufman B, Findlay M et al: A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed infammatory breast cancer (IBC). Breast Cancer Res Tr (2006) 100:S5-S5.
32. Biswas DK, Cruz AP, Gansberger E, Pardee AB: Epidermal growth factor-induced nuclear factor κB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA (2000) 97(15):8542-8547.
33. Schilder R, Sill M, Chen X, Darcy K, Decesare S, Lewandowski G, Lee R, Arciero C, Wu H, Godwin A: Phase II study of geftinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A Gynecologic Oncology Group study. Clin Cancer Res (2005) 11(15):5539-5548.
34. Reuter CW, Morgan MA, Eckardt A: Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer (2007) 96(3):408-416.
35. Cohen E, Kane M, List M, Brockstein B, Mehrotra B, Huo D, Mauer A, Pierce C, Dekker A, Vokes E: Phase II trial of geftinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res (2005) 11(23):8418-8424.
36. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR et al: Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ErbB2 rather than EGFR. Clin Cancer Res (2005) 11(22):8105-8108.
37. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK et al: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to geftinib. Proc Natl Acad Sci USA (2005) 102(21):7665-7670.
38. Erlich R: American Society of Clinical Oncology - 40th Annual Meeting (Part II) - Overnight Report, New Orleans, LA, USA. IDdb Meeting Report (2004):June 5-8.
39. Wyeth: Drug development pipeline. Company Communication (2005):January 24.
40. Wissner A, Berger DM, Boschelli DH, Floyd MB Jr, Greenberger LM, Gruber BC, Johnson BD, Mamuya N, Nilakantan R, Reich MF, Shen R et al: 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors. J Med Chem (2000) 43(17): 3244-3256.
41. Traxler P: Tyrosine kinases as targets in cancer therapy-successes and failures. Expert Opin Ther Targets (2003) 7(2):215-234.
42. IDdb author: Medicinal Chemistry - Second Joint French/Swiss Meeting, Beaune, France. IDdb Meeting Report (2003):July 1-4.
43. de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F, Pierron G et al: A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res (2007) 67(13):6253-6262.
44. Schroeder GM, Chen XT, Williams DK, Nirschl DS, Cai ZW, Wei D, Tokarski JS, An Y, Sack J, Chen Z, Huynh T et al: Identifcation of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase. Bioorg Med Chem Lett (2008) 18(6):1945-1951.
45. Guo F, Letrent SP, Sharma A: Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors. Cancer Chemother Pharmacol (2007) 60(6):799-809.
46. Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N, Emerson EO, Floyd E, Harriman S, Kath JC, Morris J et al: Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. Cancer Res (2007) 67(20):9887-9893.
47. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T et al: AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res (2004) 64(14):4931-4941.
48. Novartis R&D Pipeline: Products in development: Novartis International AG, Basel, Switzerland (2008). www.novartis.com/ research/pharmaceutical-product.shtml
49. Agus DB, Terlizzi E, Stopfer P, Amelsberg A, Gordon A: A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours. J Clin Oncol (2006) 24(18S):2074.
50. Boehringer Ingelheim: R&D Pipeline: Boehringer Ingelheim GmbH, Ingelheim, Germany (2008). www.boehringer-ingelheim.com/ corporate/research/pipeline.asp
51. Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 7(3):169-181.
52. De Groot JF, Gilbert MR, Hess KR, Hanna T, Groves M, Conrad C, Aldape K, Colman H, Puduvalli V, Yung WA: Phase II study of combination carboplatin and erlotinib in patients with recurrent glioblastoma multiforme. J Clin Oncol (2007) 25(18S):2024.
53. Sunpaweravong P, Sunpaweravong S, Sangthawan D, Puttawibul P, Mitarnun W: Combination of geftinib, cisplatin and 5-FU chemotherapy, and radiation therapy (RT) in newly-diagnosed patients with esophageal carcinoma. J Clin Oncol (2007) 25(18S):4605.
54. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ: A phase II trial of cisplatin, fxed dose-rate gemcitabine and geftinib for advanced urothelial tract carcinoma: Results of the Cancer and Leukaemia Group B 90102. BJU Int (2008) 101(1):20-25.
55. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol (2007) 25(12):1545-1552.
56. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol (2007) 25(15):1960-1966.
57. Cascinu S, Berardi R, Salvagni S, Beretta GD, Catalano V, Pucci F, Sobrero A, Tagliaferri P, Labianca R, Scartozzi M, Crocicchio F et al: A combination of geftinib and FOLFOX-4 as frst-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplifcation and NF-κB activation. Br J Cancer (2008) 98(1):71-76.
58. Meyerhardt JA, Stuart K, Fuchs CS, Zhu AX, Earle CC, Bhargava P, Blaszkowsky L, Enzinger P, Mayer RJ, Battu S, Lawrence C et al: Phase II study of FOLFOX, bevacizumab and erlotinib as frst-line therapy for patients with metastastic colorectal cancer. Ann Oncol (2007) 18(7):1185-1189.
59. Chen J, Smith M, Kolinsky K, Adames V, Mehta N, Fritzky L, Rashed M, Wheeldon E, Linn M, Higgins B: Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models. Cancer Chemother Pharm (2007) 59(5):651-659.
60. Munk M, Memon AA, Nexo E, Sorensen BS: Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis. BJU Int (2007) 99(1):196-201.
61. Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP et al: Phase I study of geftinib, irinotecan, 5-fuorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol (2007) 60(5):661-670.
62. Erjala K, Raitanen M, Kulmala J, Grénman R: Concurrent use of vinorelbine and geftinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol (2007) 133(3):169-176.
63. Failly M, Korur S, Egler V, Boulay J, Lino M, Imber R, Merlo A: Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. Mol Cancer Ther (2007) 6(2):773-781.
64. Brell JM, Matin K, Evans T, Volkin RL, Keifer GJ, Schlesselman JJ, Dranko S, Rath L, Schmotzer A, Ramanathan RK: Phase II study of geftinib and docetaxel for patients (pts) with advanced pancreatic adenocarcinoma (APC) progressing after frst-line therapy. J Clin Oncol (2007) 25(18S):4586.
65. Kwak EL, Clark JW, Chabner B: Targeted agents: The rules of combination. Clin Cancer Res (2007) 13(18 Pt 1):5232-5237.
66. Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, Wang Y et al: Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA (2008) 105(2):692-697.
67. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T et al: MET amplifcation leads to geftinib resistance in lung cancer by activating ErbBB3 signaling. Science (2007) 316(5827):1039-1043.
68. 790M mutations in EGFR mutant lung tumors with acquired resistance to geftinib or erlotinib. Proc Natl Acad Sci USA (2007) 104(52):20932-20937.
69. Mastalerz H, Chang M, Gavai A, Johnson W, Langley D, Lee FY, Marathe P, Mathur A, Oppenheimer S, Tarrant J, Tokarski JS et al: Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases. Bioorg Med Chem Lett (2007) 17(10):2828-2833.
70. Reid A, Vidal L, Shaw H, de Bono J: Dual inhibition of ErbB1 (EGFR/ HER1) and ErbB2 (HER2/neu). Eur J Cancer (2007) 43(3):481-489.
71. Tabernero J: The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res (2007) 5(3):203-220.
72. Wissner A, Fraser HL, Ingalls CL, Dushin RG, Floyd MB, Cheung K, Nittoli T, Ravi MR, Tan X, Loganzo F: Dual irreversible kinase inhibitors: Quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. Bioorg Med Chem (2007) 15(11):3635-3648.
73. Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M: Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Update (2007) 10(3):81-100.
74. Jimeno A, Kulesza P, Wheelhouse J, Chan A, Zhang X, Kincaid E, Chen R, Clark D, Forastiere A, Hidalgo M: Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of effcacy. Br J Cancer (2007) 96(6):952-959.
75. Hu W, Liu T, Xiong J, Wang C: Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells. Acta Pharmacol Sin (2007) 28(8): 1224-1230.
76. Mimeault M, Johansson SL, Vankatraman G, Moore E, Henichart JP, Depreux P, Lin MF, Batra SK: Combined targeting of epidermal growth factor receptor and hedgehog signaling by geftinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther (2007) 6(3):967-978.
77. Noble ME, Endicott JA, Johnson LN: Protein kinase inhibitors: Insights into drug design from structure. Science (2004) 303(5665): 1800-1805.
78. 790M mutation in EGFR kinase causes drug resistance by increasing the affnity for ATP. Proc Natl Acad Sci USA (2008) 105(6):2070-2075.
79. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ et al: A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res (2004) 64(18):6652-6659.
80. Liu Y, Gray NS: Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol (2006) 2(7):358-364.
81. Wissner A, Brawner Floyd MB, Rabindran SK, Nilakantan R, Greenberger LM, Shen R, Wang YF, Tsou HR: Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: Analogues of three important 4-anilino-quinazolines currently undergoing clinical evaluation as therapeutic antitumor agents. Bioorg Med Chem Lett (2002) 12(20):2893- 2897.
82. Singh P, Kumar R: Inhibitors of the epidermal growth factor receptor protein tyrosine kinase: A quantitative structure-activity relationship analysis. J Enzyme Inhib (1998) 13(2):125-134.
83. Kurup A, Garg R, Hansch C: Comparative QSAR study of tyrosine kinase inhibitors. Chem Rev (2001) 101(8):2573-2600.
84. Vema A, Panigrahi S, Rambabu G, Gopalakrishnan B, Sarma J, Desiraju G: Design of EGFR kinase inhibitors: A ligand-based approach and its confrmation with structure-based studies. Bioorg Med Chem (2003) 11(21):4643-4653.
85. Hou T, Zhu L, Chen L, Xu X: Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular feld analyses and molecular docking studies. J Chem Inf Comput Sci (2003) 43(1):273-287.
86. Chen G, Luo X, Zhu W, Luo C, Liu H, Puah C, Chen K, Jiang H: Elucidating inhibitory models of the inhibitors of epidermal growth factor receptor by docking and 3D-QSAR. Bioorg Med Chem (2004) 12(9):2409-2417.
87. Assefa H, Kamath S, Buolamwini JK: 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. J Comput Aided Mol Des (2003) 17(8):475-493.
88. Kamath S, Buolamwini J: Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors. J Med Chem (2003) 46(22):4657-4668.
89. Peng T, Pei J, Zhou J: 3D-QSAR and receptor modeling of tyrosine kinase inhibitors with fexible atom receptor model (FLARM). J Chem Inf Comput Sci (2003) 43(1):298-303.
90. Szántai-Kis C, Kövesdi I, Eros D, Bánhegyi P, Ullrich A, Kéri G, Orf L: Prediction oriented QSAR modelling of EGFR inhibition. Curr Med Chem (2006) 13(3):277-287.
91. von Ahsen O, Bomer U: High-throughput screening for kinase inhibitors. ChemBioChem (2005) 6(3):481-490.
92. Godl K, Gruss OJ, Eickhoff J, Wissing J, Blencke S, Weber M, Degen H, Brehmer D, Orf L, Horváth Z, Kéri G et al: Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res (2005) 65(15):6919- 6926.
93. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A, Cotten M, Daub H: An effcient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA (2003) 100(26):15434-15439.
94. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Muller S, Klebl B, Cotten M, Keri G, Wissing J et al: Cellular targets of geftinib. Cancer Res (2005) 65(2):379-382.
95. Keri G, Orf L, Eros D, Hegymegi-Barakonyi B, Szantai-Kis C, Horvath Z, Waczek F, Marosfalvi J, Szabadkai I, Pato J, Greff Z et al: Signal transduction therapy with rationally designed kinase inhibitors. Curr Signal Transduct Ther (2006) 1(1):67-95.
96. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, Mathieson T, Perrin J, Raida M, Rau C, Reader V et al: Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol (2007) 25(9):1035-1044.
97. ZENECA (Gibson KH): Preparation of haloanilinoquinazolines as Class I receptor tyrosine kinase inhibitors. WO-09633980 (1996).
98. PFIZER (Schnur RC, Arnold LD): Preparation of N-phenylquinazoline-4-amines as neoplasm inhibitors. WO-09630347 (2006).
99. GLAXO GROUP (McClure MS, Osterhout MH, Roschangar F, Sacchetti MJ): Preparation of quinazoline ditosylate salts as inhibitors of erbB protein tyrosine kinases. WO-2002002552 (2002).
100. WARNER-LAMBERT (Bridges AJ, Driscoll D, Klohs WD): Preparation of N-{4-(3-chloro-4-fuorophenylamino)-7-[3-(morpholin-4-yl) propoxy]quinazolin-6-yl}acrylamide as an irreversible inhibitor of tyrosine kinases. WO-2000031048 (2000).
101. Wyeth, John, and brother ltd (Rabindran SK, Gibbons JJ Jr): Antineoplastic combinations of CCI-779 and EKB-569. WO-2003020266 (2003).
102. Zeneca (Barker AJ): Quinazoline tyrosine kinase-inhibiting anticancer agents. CA-02086968 (1993).
103. Wyeth, John, and brother ltd (Wissner A, Rabindran SK, Tsou HR): A preparation of cyanoquinoline derivatives, useful as protein tyrosine kinase enzyme inhibitors (antitumor agents) US-2005059678 (2005).
104. Astra Zeneca (Hennequin LFA, Stokes ESE, Thomas AP): Preparation of 4-anilino-7-piperidinyloxyquinazolines as vascular endothelial growth factor inhibitors. WO-2001032651 (2001).
105. Ciba -GeiGy (Traxler T, Bold G, Brill WK-D, Frei J): Preparation of 7H-pyrrolo[2,3-d]pyrimidines as tyrosine protein kinase inhibitors. WO-09702266 (1997).
106. Bristol -myers Squibb (Fink BE, Gavai AV, Vite GD, Chen P, Mastalerz H, Norris DJ, Tokarski JS, Zhao Y, Han W-C): Pyrrolotriazine compounds as kinase inhibitors. WO-05066176 (2005).
107. PfiZer (Kath JC, Bhattacharya SK, Morris J): Preparation of substituted 4-quinazolinamines for the treatment of abnormal cell growth. WO-2001098277 (2001).
108. Novartis (Bold G, Capraro H-G, Caravatti G, Traxler P): Preparation of 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidines as protein tyrosine kinase inhibitors. WO-2003013541 (2003).
109. BoehrinGer InGelheim (Himmelsbach F, Langkopf E, Blech S, Jung B, Baum E, Solca F): Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof. WO-2002050043 (2002).
110. Vichem (Banhegyi P, Keri G, Orf L, Szekelyhidi Z, Waczek F): Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use. P0600706 (2008).
111. Vichem (Banhegyi P, Keri G, Orf L, Szekelyhidi Z, Waczek F): Therapeutic application of tricyclic aromatic and saturated benzo[4,5]thieno-[2,3-d]pyrimidine derivatives, as well as their therapeutically acceptable salts. P0600707 (2008)